Survodutide

What Survodutide does

Survodutide activates GLP-1 and glucagon receptors. Trials study weight loss, type 2 diabetes and fatty liver disease. Phase 3 weight-loss results are available, but it remains investigational. Nausea, vomiting and diarrhea are common, and long-term heart and liver outcomes remain uncertain.

• In phase 3 trials, adults with obesity or overweight plus a related health problem lost weight. (Studied in a trial)
• Studied for type 2 diabetes, where weight or blood sugar improved, and for fatty liver with inflammation or scarring. (Studied in a trial)
• Some people report better appetite control when adding small weekly doses to tirzepatide. (Reported by users)

Uses in the sources

• Studied for weight loss in adults with obesity or overweight plus a complication. (Studied in a trial) (source)
• Studied for type 2 diabetes and for fatty liver with inflammation or scarring. (Studied in a trial) (source)

Survodutide dosage

Typical reported dose: 0.3 mg once a week

• Phase 2 diabetes: 0.3 mg: 0.3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 0.9 mg: 0.3 mg once weekly, then 0.6 mg once weekly, then 0.9 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.8 mg: 0.3 mg once weekly, then 0.6 mg once weekly, then 0.9 mg once weekly, then 1.2 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 2.7 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 1.8 mg once weekly, then 2.4 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.2 mg twice weekly: 0.3 mg twice weekly, then 0.6 mg twice weekly, then 0.9 mg twice weekly, then 1.2 mg twice weekly twice weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)
• Phase 2 diabetes: 1.8 mg twice weekly: 0.3 mg twice weekly, then 0.6 mg twice weekly, then 0.9 mg twice weekly, then 1.2 mg twice weekly twice weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes on metformin. (source)

Highest studied: Highest published weekly SC target found: 6 mg..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Survodutide

Comes as: Community-reported powder vials.

Mixed with: One posted guide mentions bacteriostatic water; trial formulation compatibility is not established..

Common vial sizes: 10 mg. Common water amounts: 2 mL.

• 10 mg with 2 mL appears in a posted guide; it is not a manufacturer instruction or a measured prevalence.
• A vial size or water volume cannot confirm identity, sterility or actual peptide content.

Before mixing: No validated storage range for unregulated vials was found.

After mixing: No validated home-mixed stability or beyond-use time was found.

Survodutide side effects and risks

Reported side effects

• Nausea: SYNCHRONIZE MASLD: 56.2% at 6 mg vs 14.3% placebo., moderate (source)
• Vomiting: 42.5% vs 7.1% placebo in SYNCHRONIZE MASLD., moderate (source)
• Diarrhea: 29.5% vs 10.0% placebo in SYNCHRONIZE MASLD., moderate (source)
• Constipation: 28.1% vs 10.0% placebo in SYNCHRONIZE MASLD., moderate (source)
• Fatigue: 10.3% vs 5.7% placebo in SYNCHRONIZE MASLD., mild (source)
• Gallstones or gallbladder inflammation: Each: 1/146 (0.7%) vs 0/70 placebo in SYNCHRONIZE MASLD., serious (source)
• Major depression reported during treatment: 4/146 (2.7%) vs 0/70 placebo; causality is not established., serious (source)
• Heart rate increase: Seen in early studies; frequency is not given as a simple patient rate., moderate (source)
• Pancreatitis, severe allergy or dehydration-related kidney injury: GLP 1 class concerns; compound specific rare event rates remain uncertain., serious (source)

Stop and get help if

• Severe or persistent belly pain, especially into the back: Stop dosing and get urgent medical assessment.
• Trouble breathing; swelling of lips, tongue or throat: Call emergency services now.
• Chest pain, fainting or a sustained racing heart: Seek emergency care.
• Sudden vision loss or a major vision change: Seek urgent eye/emergency assessment.
• Confusion, seizure or low blood sugar that does not resolve: Call emergency services; do not take another dose.
• Repeated vomiting, inability to keep fluids down or very little urine: Get urgent care for dehydration or kidney injury.
• Belly swelling with vomiting and inability to pass stool or gas: Seek urgent medical assessment.
• Fever or spreading redness, heat or swelling after an injection: Get urgent medical care for possible infection.

Who should avoid it

• pregnant: Excluded from trials; no established pregnancy safety.
• breastfeeding: No established infant safety; avoid exposure while breastfeeding.
• tryingToConceive: Plan stopping and contraception with a clinician; no verified compound-specific washout is given here.
• under18: Pediatric safety and dosing remain limited.
• mtcOrMen2: Personal/family medullary thyroid cancer or MEN2 was excluded. Human thyroid-cancer risk is not established.
• eatingDisorderHistory: Appetite suppression may worsen restrictive eating; this is a precautionary screen.
• pancreatitisHistory: Review prior pancreatitis before exposure; this is also a GLP-1 class precaution.
• gallbladderDisease: Gallbladder symptoms need review during substantial weight loss.
• gastroparesis: Delayed stomach emptying can worsen severe stomach-motility problems.
• diabeticRetinopathy: Rapid glucose improvement can worsen existing eye disease; direct long-term risk is uncertain.
• kidneyDisease: Vomiting and diarrhea can cause dehydration and kidney injury. Special-population data are incomplete.
• liverDisease: Advanced liver disease needs specialist review; trial findings do not establish self-dosing.
• heartCondition: Heart rate rose in early trials; review rhythm problems and symptoms.
• uncontrolledBloodPressure: Review uncontrolled pressure before use; blood pressure changes and dehydration need monitoring.
• surgeryPlanned: Tell the anesthesia team about use; delayed stomach emptying can raise aspiration risk.
• other: Prior severe reaction to this compound or its ingredients should stop re-exposure.
• testedAthlete: Investigational status brings a WADA S0 prohibition at all times.
• psychiatricCondition: Major mood disorders were excluded from early trials; review symptoms and ability to eat adequately.
• seizureDisorder: Seizure disorders were excluded from the phase 2 obesity trial; direct safety evidence is limited.

Interactions

• Insulin: Additive low-glucose risk; insulin doses may need clinician adjustment.
• Sulfonylureas: Additive low-glucose risk; review dose and glucose checks.
• Other GLP-1 or related appetite injections: Overlapping actions may worsen stomach symptoms and dehydration. No verified home stack has a tested dose.
• Narrow-window oral medicines: Slower stomach emptying or vomiting may alter exposure. Monitoring needs are medicine-specific.
• Oral contraception: Vomiting may reduce pill reliability. A tirzepatide-specific backup rule cannot be assumed for this drug.
• Oral anticoagulants: Illness and poor intake may change anticoagulation. No direct interaction magnitude is established here.

Product quality risks

• No independent published assay series of online survodutide products was found.
• Indirect evidence: online semaglutide samples had 7%–14% purity and 29%–39% excess content; one had elevated endotoxin.
• FDA names this compound in warnings about unapproved research-labeled GLP-1 products of unknown quality.
• Wrong identity, wrong amount, contamination and counterfeit packaging are separate risks.

What to expect

36 registered human protocols found, including planned and unreported studies. Secondary analyses and meta-analyses reuse participants; they are not counted again.

Key studies

• First doses (Jungnik 2023): Early human results supported further dose testing. (source)
• Early repeat doses (Jungnik 2023): Early schedules produced weight loss and tolerability problems. (source)
• Early Japanese trial: Weight fell, but many could not complete dose escalation. (source)
• Phase 2 diabetes: Weight or glucose improved; stomach symptoms limited tolerability. (source)
• Phase 2 obesity: Weight or glucose improved; stomach symptoms limited tolerability. (source)
• Phase 2 MASH: Weight or glucose improved; stomach symptoms limited tolerability. (source)

Survodutide FAQ

• Is Survodutide FDA-approved? No FDA approval or dosing label found. FDA warns against research-labeled versions; “research use only” does not authorize human sale.
• How do people take it? Under the skin, once weekly. Source: reported by users, not an established dose.
• What's the difference between Survodutide and Tirzepatide? Survodutide: a weekly dual-hormone injection with phase 3 weight-loss data and frequent stomach side effects. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: people seek appetite control, energy or a broken weight-loss stall.
• Can I take it with Tirzepatide? People seek appetite control, energy or a broken weight-loss stall. Overlapping GLP-1 effects; combination doses and safety are not established. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). S0 applies to investigational substances without any governmental human-use approval.
• How long does a mixed vial last? No validated home-mixed stability or beyond-use time was found.